Printer Friendly

Research and Markets: In 2007, Boehringer Ingelheim's Branded Prescription Medicine Generated 70.9 Per Cent of Total Sales.

DUBLIN, Ireland -- Research and Markets( has announced the addition of the "Boehringer Ingelheim: Performance, Products, Pipeline and Potential" company profile to their offering.

Boehringer Ingelheim GmbH (BI) is the world's largest private pharmaceutical enterprise, encompassing more than 137 affiliates worldwide, and employing around 39,800 people. The company's activities are concentrated on two businesses: Human Pharmaceuticals and Animal Health. BI is headquartered in Ingelheim, Germany, where the company was founded in 1885.

Branded prescription medicines remain BI's most significant source of income. In 2007, this segment generated 70.9 per cent of total sales, principally driven by the success of Spiriva, Flomax and Micardis. In 2006, Abbot returned its US distribution rights for Mobic to BI due to increasing generic competition. Having once been a core part of BI's product portfolio, Mobic sales are now so low, the company no longer reports them. The losses experienced by Mobic were expected to dent BI's medium-term growth prospects, however, it now appears that the company has enough growth drivers to overcome this significant setback. Successful lifecycle management is expected to help Flomax and Sifrol continue to contribute strong sales in spite of patent loss and increased competition, thus avoiding the same fate as Mobic.

The launches of Aptivus and Cymbalta may prove vital for the Virology and CNS therapeutic areas, both of which are currently threatened by falling sales of their major products in the short-to-medium term. Aptivus and Cymbalta have been in-licensed through agreements with Pfizer and Eli Lilly, respectively, and BI continues to actively seek similar deals with other companies. However, in order to generate the maximum value from its product portfolio, BI will have to increase the productivity of its own R&D activities. Currently, BI's pipeline is dominated by line extensions for its major products. In 2007, BI increased human pharma R&D expenditure by 9.9 per cent, and it now accounts for 15.1 per cent of total sales. Through this substantial investment, the company hopes to be able to broaden its research beyond effective lifecycle management of its major products. To this end, in 2005, new pharmaceutical compounds entered the Metabolic and Oncology pipelines, a notable milestone, as previously neither therapeutic area contained any pipeline projects.

This new strategic analysis report Boehringer Ingelheim: Pipeline - Products - Performance - Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. These reports are updated with the latest data on a continuing basis and the full report is released quarterly. Once a year the report undergoes a major review in line with the company's year end.

Key Topics Covered:












Some of the Companies mentioned:

* AbGenomics Corporation

* Bayer

* Five Prime Therapeutics

* Galapagos PLC

* GlaxoSmithKline

* Medarex Inc

* Micromet AG

* Novosom AG

* Orexo AB

* Pfizer

* Vitae Pharmaceuticals Inc

For more information visit

Source: Espicom Business Intelligence Ltd
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 30, 2009
Previous Article:Research and Markets: What's Ahead for Worksite Wellness and Health Promotion in 2009 Audio Conference on CD-ROM.
Next Article:The Sant Corporation Announces 84% Revenue Growth for 2008.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters